Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function.
Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function. It was founded by a team with deep roots in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development. The company's proprietary EncompassTM platform was designed to create enhancement-targeting chimeric (ENTACTM) medicines. ENTACs take advantage of DUBs' ability to regulate proteins.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 6, 2022 | Series A | $81M | 9 | Qiming Venture Partners USA venBio Partners | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Qiming Venture Partners USA | Yes | Series A |
venBio Partners | Yes | Series A |
4BIO Capital | — | Series A |
Abingworth | — | Series A |
Arkin Bio Ventures | — | Series A |
Brandon Capital Partners | — | Series A |
Janus Henderson Investors | — | Series A |
Logos Capital | — | Series A |
Surveyor Capital | — | Series A |